News
04-10-2013, 12:51 AM
A molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company.
More... (http://www.news-medical.net/news/20130410/CvergenX-to-develop-radiosensitivity-test-to-better-radiation-therapy-decisions-for-patients-with-cancer.aspx)
More... (http://www.news-medical.net/news/20130410/CvergenX-to-develop-radiosensitivity-test-to-better-radiation-therapy-decisions-for-patients-with-cancer.aspx)